Silexion net loss widens 44% to USD 3.6 million in Q2 FY26
SLXN•Cash balance declines
Cash and cash equivalents fell to USD 2.2 million at June 30 from USD 6 million at Dec. 31.
Trial progress and financing update
SIL204 entered an active Phase 2/3 trial in locally advanced pancreatic cancer, with the first site initiated at Tel Aviv Sourasky Medical Center in July.
Management said a registered public offering closed Aug. 13 with gross proceeds of about USD 2.5 million, supporting Nasdaq listing compliance.
Q2 loss widens as operating costs rise
Silexion posted a Q2 net loss of USD 3.6 million, widening 44% year over year, as research and development climbed to USD 2.2 million.
General and administrative expense rose 15.4% to USD 1.5 million, while financial results swung to net income of about USD 100,000.
